Pilocarpine hydrochloride 0.4%
Glaucoma · Rx
RxGlaucomaGlaucoma CholPreservative-free option Dark green cap
| Strength | 0.4% |
|---|---|
| Typical quantity | 30 x 0.4 mL vials (30-day) |
| Cash cost / month | Moderate · ~$20-100 |
| Drug class | Cholinergic (muscarinic) agonist / miotic, presbyopia formulation |
| Mechanism of action | Direct muscarinic agonist; contracts the iris sphincter for a pinhole (miotic) effect that extends depth of focus for near vision. Lower concentration than Vuity (1.25%), formulated with dual lubricants (hyaluronic acid + HPMC) for comfort. |
| Indication / reason for use | Presbyopia. A distinct product from Vuity, not indicated for glaucoma or angle-closure. |
| Usual adult dosing | 1 drop each eye, once or twice daily as needed. Onset ~20 min, duration up to ~8 h. |
| Preservative | Preservative-free, single-use vials , a preservative-free option exists |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | Brow ache / accommodative spasm, dim vision at night (miosis), headache, eye redness; the usual miotic cautions apply at higher doses, but are minimal at this low concentration. |
| Contraindications & cautions | Conditions where miosis is undesirable (e.g. acute uveitis); the same relative cautions as other miotics for peripheral retinal disease. |
| Pregnancy / lactation | Limited data; use only if clearly needed. |
| Pregnancy category (older labels) | No letter category on the current label. From DailyMed labels, checked Nov 2026. |
| Trade names | Qlosi |
| Practice notes | FDA-approved October 2023 (NEAR-1/NEAR-2 trials), available in the US since April 2025. A second FDA-approved presbyopia drop, competing directly with Vuity (1.25% pilocarpine, once daily). |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.